BioCentury
ARTICLE | Clinical News

VLTS Phase IIb IL-2 data

December 3, 2001 8:00 AM UTC

Valentis (VLTS) said the final analysis of an 80-patient European Phase IIb trial of its IL-2 GeneMedicine gene therapy to treat head and neck cancer failed to confirm previously reported interim resu...